real-world evidence

By Dave Muoio March 14, 2019
Clinical trial data analysis company TriNetX has raised $40 million in a Series D funding round led by Merck Global Health Innovation Fund. Also participating in the round were new investors Mitsui & Co. and Itochu Technology Ventures, and returning backers MPM Capital, F2 Ventures and Deerfield Management. Announced yesterday, the new investments bring TriNetX’s total funding to $102 million...

Verisense by Shimmer IMU (Photo courtesy Shimmer)

By Jonah Comstock February 19, 2019
Shimmer, a Dublin-based wearable sensor company, has launched a new sensor platform for clinical trials called VeriSense. At launch, the platform will work with Shimmer's IMU, or inertial measurement unit, sensor, which can measure activity and sleep from the wrist, as well as network with sensors elsewhere on the body to monitor musculoskeletal and neurological conditions. The company has been...
By Dave Muoio February 5, 2019
New York City-based Aetion, which makes an analytics platform to assess real-world evidence from a range of sources, has raised $27 million in a funding round supported by new backers Sanofi, UCB, McKesson Ventures and Horizon Health Services, according to a release. Prior investors including NEA, Flare Capital and Lakestar also participated. An add-on to prior funding from last year, today’s...
By Jonah Comstock September 15, 2017
One of the biggest promises of mobile health apps and wearables is the sheer amount of data they collect. As that dataset grows, a number of different stakeholders are taking an interest in it, among them patients themselves, doctors, and clinical researchers. The latter is the focus of a new report out today from the Duke-Margolis Center for Health Policy. “Under a collaborative agreement with...
By Jonah Comstock March 31, 2017
The health subcommittee of the House Energy and Commerce committee met this week to question Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, about the medical device user fee amendments (MDUFA). MDUFA is an agreement between the FDA and industry in which the FDA agrees to do certain things in return for industry groups supporting the agency’s work by paying fees...